Epiomic Epidemiology Series: Prader-Willi Syndrome Forecast in 9 Major Markets 2016-2026

February 2016 | 40 pages | ID: EB596C3CF4EEN
Black Swan Analysis limited

Abstracts

Prader-Willi syndrome (PWS) is a genetic disease caused by the loss of function of several genes in a particular region of chromosome 15, affecting many parts of the body. These genes provide instructions for making molecules called small nucleolar RNAs (snRNAs) which have a variety of functions, including helping to regulate other types of RNA molecules in infancy.

This report provides the current prevalent population for Prader-Willi disease across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Prader-Willi disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Prader-Willi disease include:

• Cardiovascular Problems
• Obstructive sleep apnoea and respiratory disorders
• Diabetes Type II
• Autism Spectrum Disorder Behavioural Characteristics
• Seizures
• Hip dysplasia
• Scoliosis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Prader-Willi disease’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Prader-Willi disease and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Prader-Willi disease’s prevalent population.
• Identify sub-populations within Prader-Willi disease which require treatment.
• Gain an understanding of the specific markets that have the largest number Prader-Willi disease patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Co-morbid Conditions/ Features Associated with the Disease
Methodology for Quantification of Patient Numbers
  Additional data available on request
Top-Line Prevalence for Prader-Willi Syndrome
Main Complications and Features of Prader-Willi Patients
  Nutritional Phases of PWS
  Level of Cognitive Functions of PWS Patients
  Type of Mutation affecting chromosome 15 in PWS Patients
  Cardiovascular Problems in PWS Patients
  Respiratory Problems in PWS Patients
  Intellectual Disability and Neurological Disorders in PWS Patients
  Motor and Skeletal Impairments in PWS Patients
Abbreviations used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES & FIGURES

Prevalence of PWS, total (000s)
Prevalence of PWS, males (000s)
Prevalence of PWS, females (000s)
Prevalence of Nutrition Phases of PWS, total (000s)
Prevalence of Cognitive Function of PWS patients by IQ score, total (000s)
Prevalence of Type of Mutation of PWS patients, total (000s)
Prevalence of Cardiovascular problems in PWS Patients, total (000s)
Prevalence of Hypertension in PWS Patients, total (000s)
Prevalence of Obstructive Sleep Apnoea/Respiratory problems in PWS Patients, total (000s)
Prevalence of Autism spectrum disorder behavioural characteristics in PWS patients, total (000s)
Prevalence of Seizures in PWS patients, total (000s)
Prevalence of Psychotic Disorders in PWS patients, total (000s)
Prevalence of Hip dysplasia in PWS patients, total (000s)
Prevalence of Scoliosis in PWS patients, total (000s) total (000s)
Abbreviations and Acronyms used in the Report
USA Prevalence of PWS by 5-yr age cohort, males (000s)
USA Prevalence of PWS by 5-yr age cohort, females (000s)
France Prevalence of PWS by 5-yr age cohort, males (000s)
France Prevalence of PWS by 5-yr age cohort, females (000s)
Germany Prevalence of PWS by 5-yr age cohort, males (000s)
Germany Prevalence of PWS by 5-yr age cohort, females (000s)
Italy Prevalence of PWS by 5-yr age cohort, males (000s)
Italy Prevalence of PWS by 5-yr age cohort, females (000s)
Spain Prevalence of PWS by 5-yr age cohort, males (000s)
Spain Prevalence of PWS by 5-yr age cohort, females (000s)
United Kingdom Prevalence of PWS by 5-yr age cohort, males (000s)
United Kingdom Prevalence of PWS by 5-yr age cohort, females (000s)
Brazil Prevalence of PWS by 5-yr age cohort, males (000s)
Brazil Prevalence of PWS by 5-yr age cohort, females (000s)
Japan Prevalence of PWS by 5-yr age cohort, males (000s)
Japan Prevalence of PWS by 5-yr age cohort, females (000s)
India Prevalence of PWS by 5-yr age cohort, males (000s)
India Prevalence of PWS by 5-yr age cohort, females (000s)